報價延遲最少15分鐘:2025/04/12 05:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3543 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.87/-0.71
|
|
企業價值
7.45M
|
| 資產負債 |
|
每股賬面淨值
0.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 05:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies. |